CL2013000347A1 - Poblacion de microparticulas que comprenden un corticoesteroide clase b incorporado en una matriz formada por un copolimero de acido lactico y acido glicolico, donde dicho corticoesteroide comprende entre 22% a 28% de las microparticulas; preparacion de liberacion controlada; formulacion; y metodo de fabricacion. - Google Patents

Poblacion de microparticulas que comprenden un corticoesteroide clase b incorporado en una matriz formada por un copolimero de acido lactico y acido glicolico, donde dicho corticoesteroide comprende entre 22% a 28% de las microparticulas; preparacion de liberacion controlada; formulacion; y metodo de fabricacion.

Info

Publication number
CL2013000347A1
CL2013000347A1 CL2013000347A CL2013000347A CL2013000347A1 CL 2013000347 A1 CL2013000347 A1 CL 2013000347A1 CL 2013000347 A CL2013000347 A CL 2013000347A CL 2013000347 A CL2013000347 A CL 2013000347A CL 2013000347 A1 CL2013000347 A1 CL 2013000347A1
Authority
CL
Chile
Prior art keywords
microparticles
corticosteroid
population
formulation
copolymer
Prior art date
Application number
CL2013000347A
Other languages
English (en)
Inventor
Neil Bodick
Robert C Blanks
Anjali Kumar
Michael D Clayman
Mark Moran
Original Assignee
Flexion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flexion Therapeutics Inc filed Critical Flexion Therapeutics Inc
Publication of CL2013000347A1 publication Critical patent/CL2013000347A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2013000347A 2010-08-04 2013-02-04 Poblacion de microparticulas que comprenden un corticoesteroide clase b incorporado en una matriz formada por un copolimero de acido lactico y acido glicolico, donde dicho corticoesteroide comprende entre 22% a 28% de las microparticulas; preparacion de liberacion controlada; formulacion; y metodo de fabricacion. CL2013000347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37066610P 2010-08-04 2010-08-04

Publications (1)

Publication Number Publication Date
CL2013000347A1 true CL2013000347A1 (es) 2013-09-06

Family

ID=45559826

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000347A CL2013000347A1 (es) 2010-08-04 2013-02-04 Poblacion de microparticulas que comprenden un corticoesteroide clase b incorporado en una matriz formada por un copolimero de acido lactico y acido glicolico, donde dicho corticoesteroide comprende entre 22% a 28% de las microparticulas; preparacion de liberacion controlada; formulacion; y metodo de fabricacion.

Country Status (24)

Country Link
US (8) US20120282298A1 (es)
EP (2) EP3701941A1 (es)
JP (3) JP5873492B2 (es)
KR (2) KR101927551B1 (es)
CN (2) CN107669640A (es)
AR (1) AR082471A1 (es)
AU (1) AU2011285691B2 (es)
BR (1) BR112013002601A2 (es)
CA (2) CA2807150C (es)
CL (1) CL2013000347A1 (es)
CO (1) CO6700827A2 (es)
ES (1) ES2799419T3 (es)
IL (1) IL224547B (es)
MX (1) MX353466B (es)
MY (1) MY171929A (es)
NZ (1) NZ607797A (es)
PH (1) PH12013500215B1 (es)
RU (2) RU2018100114A (es)
SG (3) SG10201607891VA (es)
TW (2) TWI548412B (es)
UA (1) UA111162C2 (es)
UY (1) UY33546A (es)
WO (1) WO2012019009A1 (es)
ZA (1) ZA201300831B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
HUE066287T2 (hu) 2011-04-25 2024-07-28 Geneora Pharma Shijiazhuang Co Ltd Nyújtott leadású mikroszféra risperidon készítmény
EP2739287B1 (en) * 2011-08-04 2017-07-05 Flexion Therapeutics, Inc. Corticosteroids for the treatment of joint pain
US8927529B2 (en) * 2012-01-30 2015-01-06 SpineThera Treatment of back pain by injection of microparticles of dexamethasone acetate and a polymer
JP6215354B2 (ja) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ， インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
WO2014144309A1 (en) 2013-03-15 2014-09-18 Oakwood Laboratories Sustained release microspheres and method of producing the same
WO2014153384A1 (en) * 2013-03-19 2014-09-25 Flexion Therapeutics, Inc. Corticosteroid formulations for the treatment of joint pain and methods of use thereof
CN110575445B (zh) * 2013-03-21 2023-08-18 优普顺药物公司美国分部 可注射的持续释放组合物及其用于治疗关节炎症及相关疼痛的方法
WO2015018461A1 (fr) * 2013-08-09 2015-02-12 Genbiotech Compositions therapeutiques comprenant d'acide hyaluronique
CN105764539B (zh) * 2013-11-27 2022-03-11 伊西康有限责任公司 具有精确可控的吸收速率的吸收性聚合物共混物组合物、加工方法、以及从其得到的尺寸上稳定的医疗装置
CN106132399B (zh) * 2014-04-08 2020-05-12 帝斯曼知识产权资产管理有限公司 用于治疗关节炎病症的可生物降解的聚酯酰胺
TWI772659B (zh) 2015-01-21 2022-08-01 美商桑紐爾製藥公司 醫藥配方
WO2016198351A1 (en) * 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
US20170079985A1 (en) 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
UY36948A (es) * 2015-10-13 2017-05-31 Flexion Therapeutics Inc Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial
AU2016343952A1 (en) 2015-10-27 2018-05-10 Eupraxia Pharmaceuticals Inc. Sustained release formulations of local anesthetics
WO2017160818A1 (en) 2016-03-14 2017-09-21 Flexion Therapeutics, Inc. Triamcinolone acetonide formulations for joint pain in diabetics
WO2018112408A1 (en) * 2016-12-15 2018-06-21 Flexion Therapeutics, Inc. Fluticasone formulations and methods of use thereof
CN106727358A (zh) * 2017-01-24 2017-05-31 广州帝奇医药技术有限公司 阿立哌唑及其衍生物的缓释组合物与该缓释组合物的制备方法
CN106983733A (zh) * 2017-03-08 2017-07-28 江苏富泽药业有限公司 曲安奈德plga缓释微球注射剂、其制备方法及其在制备治疗骨关节炎疼痛药物中的应用
US20200009156A1 (en) * 2017-03-17 2020-01-09 Flexion Therapeutics, Inc. Fluticasone extended-release formulations and methods of use thereof
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
US20190336511A1 (en) * 2018-05-02 2019-11-07 Georgiy Brusovanik Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole
EP3820479B1 (en) 2018-07-09 2026-03-11 Taiwan Liposome Co., Ltd. Methods to reduce complications of intra-articular steroid
RU2703257C1 (ru) * 2018-12-04 2019-10-16 Закрытое акционерное общество "СКАЙ ЛТД" Способ лечения воспалительных процессов суставов и простатита
CN109700770B (zh) * 2019-01-31 2021-02-12 浙江圣兆药物科技股份有限公司 一种曲安奈德微球制剂及其制备方法
KR102377975B1 (ko) * 2019-03-19 2022-03-23 (주)리젠바이오텍 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법
WO2020189886A2 (ko) 2019-03-19 2020-09-24 (주)리젠바이오텍 스테로이드계 약물을 포함하는 생분해성 고분자 미세입자 및 이의 제조 방법
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
CN113795246B (zh) * 2019-05-06 2024-10-11 福多兹制药公司 用于治疗关节疼痛和炎症的可注射缓释制剂
EP3976106A4 (en) 2019-05-31 2023-01-11 DOSE Medical Corporation BIOERODABLE POLYESTER-POLYMER IMPLANTS AND ASSOCIATED METHODS OF USE
CN110237052B (zh) * 2019-07-11 2021-07-13 苏州大学 一种醋酸曲安奈德缓释微球及其制备方法
WO2021026289A1 (en) 2019-08-08 2021-02-11 Avidence Therapeutics, Inc. Microsphere-Based Injectible Celecoxib Formulation
CN111803647A (zh) * 2020-08-14 2020-10-23 山东谷雨春生物科技有限公司 一种治疗退行性关节炎的药物及其制备方法
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
GB202104224D0 (en) 2021-03-25 2021-05-12 Medincell Pharmaceutical composition
AU2022243564B2 (en) * 2021-03-26 2025-11-20 The Regents Of The University Of California Immunoregulatory microparticles for modulating inflammatory arthritides
WO2022219089A1 (en) 2021-04-16 2022-10-20 Fondazione Istituto Italiano Di Tecnologia Polymeric microparticles for the local treatment of chronic inflammatory diseases
EP4366726A1 (en) 2021-07-06 2024-05-15 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
JP2025535174A (ja) * 2022-10-17 2025-10-22 インベンテージ ラボ インコーポレイテッド 炎症性疾患の治療または予防のための徐放型注射用組成物およびその製造方法
WO2026097095A1 (en) * 2024-11-04 2026-05-07 Simplybreathe L.L.C. Drug eluting compositions and methods of making and using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
WO1995011009A1 (en) 1993-10-22 1995-04-27 Genentech, Inc. Method for preparing microspheres comprising a fluidized bed drying step
ATE212830T1 (de) 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
EP1010435B1 (en) 1997-09-05 2010-11-03 Maruho K.K. Nanocapsule preparations for treating intraarticular diseases
JPH11222425A (ja) * 1997-10-27 1999-08-17 Ss Pharmaceut Co Ltd 関節疾患治療用関節内投与製剤
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
CN1222318C (zh) 2000-11-06 2005-10-12 旭化成株式会社 制剂用纤维素粒子
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
AU2002232824A1 (en) 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
US20040022853A1 (en) 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
EP1567127A4 (en) 2002-10-17 2007-02-21 Alkermes Inc METHOD FOR MODIFYING THE RELEASE PROFILE OF COMPRESSED RELATED COMPOSITION COMPOSITIONS
AU2004222340B2 (en) 2003-03-14 2009-11-12 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
JP2007500243A (ja) 2003-06-09 2007-01-11 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 成長ホルモンの増進された経粘膜送達のための組成物および方法
WO2005032523A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20090324678A1 (en) * 2004-07-16 2009-12-31 Spinal Restoration, Inc. Methods and kits for treating joints and soft tissues
US7758778B2 (en) 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
WO2007030545A2 (en) 2005-09-07 2007-03-15 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved release rates
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
WO2007084418A2 (en) 2006-01-13 2007-07-26 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
MX2009003661A (es) * 2006-10-06 2009-04-22 Baxter Int Microcapsulas que contienen microparticulas modificadas en la superficie y metodos para formar y utilizar las mismas.
US20080317805A1 (en) 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US20110206773A1 (en) 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
WO2009150136A1 (de) 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Neue einbettungspartikel für die inhalation
EP2331082B1 (en) * 2008-09-11 2021-01-06 Evonik Corporation Solvent extraction microencapsulation with tunable extraction rates
US20100189763A1 (en) 2009-01-23 2010-07-29 Heather Nettles Controlled release systems from polymer blends
EP2512487A4 (en) 2009-12-15 2013-08-07 THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю

Also Published As

Publication number Publication date
UA111162C2 (uk) 2016-04-11
UY33546A (es) 2012-02-29
US20120288534A1 (en) 2012-11-15
CO6700827A2 (es) 2013-06-28
WO2012019009A1 (en) 2012-02-09
US9555047B2 (en) 2017-01-31
EP3701941A1 (en) 2020-09-02
KR20180132159A (ko) 2018-12-11
SG187665A1 (en) 2013-03-28
MX353466B (es) 2018-01-12
TW201219039A (en) 2012-05-16
CA2956556A1 (en) 2012-02-09
US10624905B2 (en) 2020-04-21
RU2013109362A (ru) 2014-09-10
US20150025050A1 (en) 2015-01-22
US20120282298A1 (en) 2012-11-08
CN107669640A (zh) 2018-02-09
KR20130093101A (ko) 2013-08-21
US20140356437A1 (en) 2014-12-04
TW201703762A (zh) 2017-02-01
JP2016028070A (ja) 2016-02-25
CN103260603B (zh) 2017-11-10
MY171929A (en) 2019-11-07
PH12013500215A1 (en) 2013-03-11
BR112013002601A2 (pt) 2016-06-07
NZ607797A (en) 2014-12-24
ZA201300831B (en) 2014-10-29
EP2600836B1 (en) 2020-04-22
US9949987B2 (en) 2018-04-24
JP2019059752A (ja) 2019-04-18
CA2807150A1 (en) 2012-02-09
US20170182068A1 (en) 2017-06-29
SG10201602789XA (en) 2016-05-30
RU2642279C2 (ru) 2018-01-24
MX2013001433A (es) 2013-06-03
IL224547B (en) 2020-09-30
TWI630001B (zh) 2018-07-21
SG10201607891VA (en) 2016-11-29
AU2011285691A1 (en) 2013-03-21
US20170135957A1 (en) 2017-05-18
AU2011285691B2 (en) 2015-10-01
EP2600836A1 (en) 2013-06-12
US20180311260A1 (en) 2018-11-01
RU2018100114A (ru) 2019-02-20
CN103260603A (zh) 2013-08-21
US20140242170A1 (en) 2014-08-28
TWI548412B (zh) 2016-09-11
US8828440B2 (en) 2014-09-09
EP2600836A4 (en) 2014-01-15
AR082471A1 (es) 2012-12-12
JP5873492B2 (ja) 2016-03-01
US9555048B2 (en) 2017-01-31
PH12013500215B1 (en) 2020-01-24
ES2799419T3 (es) 2020-12-17
JP2013535489A (ja) 2013-09-12
CA2807150C (en) 2017-03-14
KR101927551B1 (ko) 2018-12-10

Similar Documents

Publication Publication Date Title
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
BR112014013175A8 (pt) composições de liberação prolongada baseadas em lipídios anfipáticos e processo para preparar comprimidos de composição de liberação prolongada
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
BR112012008164A2 (pt) método para a preparação de ácido 2,5-furanodicarbloxílico e seus ésteres
WO2013105101A8 (en) Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same
CL2015000893A1 (es) Formulación de una forma farmacéutica sólida de desintegración rápida que comprende carbonato de calcio funcionalizado, un ingrediente activo y por lo menos un desintegrante; y método para su fabricación.
BRPI0906317A2 (pt) Sistema intra-uterino para períodos longos de inserção dentro da cavidade uterina, método para fabricar um sistema intra-uterino e método para liberar uma substância terapeuticamente eficaz para uma fêmea de mamífero.
CO7061080A2 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistématica, métodos y usos de las mismas
EP2779996C0 (en) DRUG DELIVERY SYSTEM PROVIDING PROLONGED DELIVERY OF BIOACTIVE AGENTS
MX344128B (es) Microcapsulas estabilizadas con nucleo, metodo para su preparacion y usos de las mismas.
JP2013005803A5 (es)
RU2018129725A (ru) Изделия, высвобождающие активный ингредиент
AR087871A1 (es) Una composicion farmaceutica de rapida disolucion
WO2013052647A3 (en) Formulations and uses of retinoic acid receptor selective agonists
BR112014026149A2 (pt) método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo.
PE20140255A1 (es) Tableta dispersable en forma oral
ZA200807354B (en) Dividable galenical form allowing modified release of the active ingredient
FI20116334L (fi) Eukaryottiset solut ja menetelmä glykolihapon valmistamiseksi
AR083328A1 (es) Particula de suministro
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
MD4563B1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
CO7190241A2 (es) Procedimiento de fabricación de una forma de dosificación farmaceútica que comprende nifedipina y candesartán cilexetilo
PL2827726T3 (pl) Wodny produkt zawierający mikrokapsułki zawierające olej oraz sposób ich wytwarzania
CR8912A (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
WO2012106016A3 (en) Oral care compositions